multiple sclerosis. multiple sclerosis
Conditions
Interventions
Fingolimode,0.5 mg,once daily,oral,for 6 months.
Treatment - Drugs
Fingolimode,0.5 mg,once daily,oral,for 6 months
Sponsors
Deputy of Research and Technology of Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: age 18-50 years; definite M.S confirmed by neurologist with relapsing remitting type; disease must be in remission; at least one month after corticostroid therapy; follow up shouldbe possible and patients must be reachable. exclusion criteria: any underlying pulmonary,hepatic,renal or orthopedic; EDSS score>5.5; during follow up events that affect depression happen to the patients.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fatigue severity. Timepoint: before intervention,3 months after initiation of intervention,6 months after initiation of intervention. Method of measurement: fatigue severity scale.;Degree of depression. Timepoint: before intervention,3 months after initiation of intervention,6 months after initiation of intervention. Method of measurement: beck standard questionare. | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver enzymes concentrations. Timepoint: Before initiation of study,every month for the first 3 months,then every 3 months so on. Method of measurement: Liver function test.;Lymphositic count. Timepoint: Before initiation of study,every month for the first 3 months,then every 3 months after. Method of measurement: CBD-diff. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFaezeh Nalchi
Kermanshah University of Medical Sciences, medical faculty
Outcome results
None listed